OncoMatch/Clinical Trials/NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Is NCT04686305 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for locally advanced or metastatic non-small cell lung cancer.
Treatment: T-DXd · Durvalumab · Cisplatin · Carboplatin · Pemetrexed · Volrustomig · Rilvegostomig — DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
HER2 overexpression status as determined by central review of tumor tissue
Excluded: HER2 (ERBB2) mutation
HER2 mutation if previously known
Disease stage
Metastatic disease required
Histologically documented unresectable locally advanced/metastatic non-squamous NSCLC
Performance status
WHO/ECOG 0–1
Prior therapy
Must have received: systemic therapy — recurrent or metastatic
Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting
Cannot have received: anti-PD-1 therapy
Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting
Cannot have received: anti-PD-L1 therapy
Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting
Cannot have received: anti-CTLA-4 therapy
Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting
Cannot have received: anti-TIGIT therapy
Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting
Cannot have received: experimental immunotherapy
Part 3, Part 4 and Part 5 patients must not have had prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
Liver function
Cardiac function
No medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (NYHA Class II to IV), clinically important cardiac arrhythmias, or recent (< 6 months) cardiovascular event including stroke. For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (NYHA Class > II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.
Has protocol defined adequate organ and bone marrow function. Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (New York Heart Association Class II to IV), clinically important cardiac arrhythmias, or a recent (< 6 months) cardiovascular event including stroke. For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class > II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Newport Beach, California
- Research Site · Orange, California
- Research Site · Santa Rosa, California
- Research Site · Westwood, Kansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify